跳至主要内容
临床试验/NCT05397795
NCT05397795Unknown3 期

COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES

Alexandria University0 个研究点目标入组 160 人开始时间: 2022年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
入组人数
160
主要终点
Number of metaphase II oocytes retrieved.

研究概览

简要总结

Poor ovarian responders (POR) include a significant proportion of women referred for IVF treatments (ranging from 9 to 24 %), most of whom are in late reproductive age.

In fact the live birth rate in the entire POR category is poor (about 6 % per cycle). However patients <40 years have a significantly better prognosis compared to older patients, mainly due to better oocyte quality.Attempts to improve IVF cycle outcomes for poor responders included modifying the steps of ovarian stimulation protocols , such as different luteal phase pretreatments, increasing ovarian stimulation doses, as well as addition of various supplements. So far, most of the modifications had limited success, therefore, optimal protocol for poor responders has remained elusive.

Final oocyte maturation trigger is one of the most important key success factors in assisted reproductive technologies (ARTs). Oocyte maturation refers to a release of meiotic arrest that allows oocytes to advance from prophase I to metaphase II of meiosis. Luteinizing Hormone (LH) surge by dismantling the gap junctions between granulosa cells and oocyte inhibits the flow of maturation inhibitory factors into ooplasm and causes drop in concentration of cAMP. Decreased concentration of cyclic AMP (cAMP) in turn increases concentration of Ca and maturation-promoting factor (MPF), which are essential for the resumption of meiosis in oocyte and disruption of oocyte-cumulus complex triggering follicular rupture and ovulation about 36 h the LH surge.

The aim of the study is to compare the oocyte yield , oocyte quality and the ongoing pregnancy rate between dual trigger treatment (combination of gonadotrophin-releasing hormone (GnRH) agonist and human chorionic gonadotrophin) and human chorionic gonadotrophin alone in PORs undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF-ICSI) cycles using a GnRH-antagonist protocol.

详细描述

Poor ovarian responders (POR) include a significant proportion of women referred for IVF treatments (ranging from 9 to 24 %), most of whom are in late reproductive age.(1,2) According to the "Bologna criteria", patients are classified as POR based on three conditions: if two or more of the following features are present: 1) advanced maternal age (>40 years); 2) a previous poor ovarian response (cycles cancelled or <3 oocytes with a conventional protocol); 3)an abnormal ovarian reserve test (antral follicle count 5-7 follicles or anti-Mullerian hormone 0.5-1.1 ng/ ml). Two of these criteria are required for a POR diagnosis. In addition, two cycles with POR after maximal stimulation are sufficient to classify a patient as a poor responder even in the absence of other criteria mentioned. (3)

In fact the live birth rate in the entire POR category is poor (about 6 % per cycle).(4,5) however patients <40 years have a significantly better prognosis compared to older patients, mainly due to better oocyte quality.(6) Attempts to improve IVF cycle outcomes for poor responders included modifying the steps of ovarian stimulation protocols , such as different luteal phase pretreatments, increasing ovarian stimulation doses, as well as addition of various supplements. So far, most of the modifications had limited success, therefore, optimal protocol for poor responders has remained elusive.(7)

ESHRE in 2019 stated GnRH antagonists and GnRH agonists are equally recommended for predicted low responders. (8)

Final oocyte maturation trigger is one of the most important key success factors in assisted reproductive technologies (ARTs). Oocyte maturation refers to a release of meiotic arrest that allows oocytes to advance from prophase I to metaphase II of meiosis. Luteinizing Hormone (LH) surge by dismantling the gap junctions between granulosa cells and oocyte inhibits the flow of maturation inhibitory factors into ooplasm and causes drop in concentration of cyclic AMP (cAMP) . Decreased concentration of cAMP in turn increases concentration of Ca and maturation-promoting factor (MPF), which are essential for the resumption of meiosis in oocyte and disruption of oocyte-cumulus complex triggering follicular rupture and ovulation about 36 h the LH surge.(9)

Until now, administering 5000 IU to 10,000 IU of hCG 34-36 h prior to oocyte retrieval remained the standard protocol for the induction of final oocyte maturation in IVF cycles worldwide. Traditionally, human chorionic gonadotropin (hCG) has been the trigger of choice for oocyte maturation due to its molecular and biological similarity with LH.(10)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •Women with a spontaneous normal menstrual cycle and a normal uterine cavity.
  • •Body mass index (BMI) <
  • •Age less than
  • •Anti-Mullerian Hormone (AMH) ≤ 1.1 ng/ ml
  • •Antral Follicle Count (AFC) ≤ 7 follicles

排除标准

  • •Comorbidities including, hypertension, Diabetes Mellitus or other endocrinopathies.
  • •Surgically retrieved sperms.
  • •Communicating hydrosalpinx.

研究组 & 干预措施

Group(A)

Experimental

subjects will be triggered by 10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly.

干预措施: 10000 IU hCG (Choriomon5000 IU; IBSA) (Drug)

Group(B)

Experimental

subjects will be triggered by 10000 IU of hCG (Choriomon5000 IU; IBSA) intramuscular injection in addition to the GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.

干预措施: 10000 IU hCG (Choriomon5000 IU; IBSA) (Drug)

Group(B)

Experimental

subjects will be triggered by 10000 IU of hCG (Choriomon5000 IU; IBSA) intramuscular injection in addition to the GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.

干预措施: Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) (Drug)

结局指标

主要结局

Number of metaphase II oocytes retrieved.

时间窗: On 1 day of oocyte retrieval

Number of metaphase II oocytes retrieved

次要结局

  • Implantation rate(Between the 5th to 6th weeks of gestation.)
  • Ongoing pregnancy rates(20 weeks of gestation.)
  • Maturity index(On 1 day of oocyte retrieval)
  • Total number of oocytes(On 1 day of oocyte retrieval)
  • Ratio between number of follicles seen on day of trigger and number of oocytes retrieved(On 1 day of oocyte retrieval)
  • Fertilization rate(On 1 day after oocyte retrieval)
  • Cancellation rate(Folliculometry on day 8 revealed no growing follicles, serum estradiol level less than 150 pg/mL on the day of hCG administration, no oocytes were retrieved, or if fertilization failed)
  • Number of transferred embryos(On 1 day of embryo transfer)
  • Number of obtained embryos(On 1 day after oocyte retrieval)
  • Day of transfer(Two to five days after oocyte retrieval)
  • Quality of embryos transferred(On 1 day of embryo transfer)
  • Chemical pregnancy rate(Fourteen days after embryo transfer)
  • Clinical pregnancy rates(Between the 5th to 6th weeks of gestation.)

研究者

申办方类型
Other
责任方
Sponsor

相似试验